發展樣品直接進樣之毛細管電泳法對人體血漿中piracetam和levetiracetam之同時分析研究與臨床應用

Simultaneous determination of piracetam and levetiracetam in human plasma by micellar electrokinetic chromatography with direct injection

楊娟明(Chuan-Ming Yang)

指導教授 ： 陳素惠

高雄醫學大學/藥學院/藥學研究所/碩士(2012年)

摘要

本研究是利用樣品直接取樣與微胞電動層析之毛細管電泳法（micellar electrokinetic chromatography; MEKC）建立一個簡單、快速可以同時分析pyrrolidone骨架之piracetam和levetiracetam藥物之定量分析。樣品無需經過任何前處理步驟，直接以壓力注入毛細管中。多種影響分離的參數皆在研究中加以討論，包括： Tris(hydroxymethyl)aminomethane (Tris)緩衝溶液的濃度與pH值、sodium dodecyl sulfate (SDS)濃度、甲醇濃度、以及樣品注射量。經過方法驗證後，最佳的分析條件為樣品注射量1.3 psi，5秒、分離電壓為16 kV之下，背景電解質為60 mM Tris緩衝溶液（pH 10），內含有260 mM SDS以及20%甲醇。分離控制在25?aC，piracetam和levetiracetam於10分鐘內可有效分離。使用imidazole作為內部標準品（Internal standard; IS），piracetam與levetiracetam之檢量線濃度範圍建立在5.0–200.0 ?慊/mL，血漿中piracetam與levetiracetam的偵測極限均為1.0 ?慊/mL。本篇分析方法具有良好的精密度與準確度，也實際應用於病患血漿中piracetam與levetiracetam濃度之分析。

關鍵字

樣品直接取樣 ； 微胞電動層析法 ； piracetam ； levetiracetam ； pyrrolidone

並列摘要

A simple micellar kinetic chromatography (MEKC) method for simultaneous determination of two pyrrolidone family compounds, piracetam and levetiracetam in human plasma is described in this study. The biological matrix was injected without any sample pretreatment. Several parameters affecting the separation of the drugs were studied, including the concentration and the pH value of the Tris(hydroxymethyl)aminomethane (Tris) buffer, the concentration of sodium dodecyl sulfate (SDS) and methanol, also with the sample volume.
After method development, the separation was carried out less than 10 min using 60 mM Tris buffer (pH 10) containing 260 mM SDS and 20% methanol at 16 kV (injection 1.3 psi, 5 s). Using imidazole as an internal standard (IS), the linear range of the method was between 5.0 and 200.0 ?慊/mL. The detection limit of piracetam and levetiracetam in plasma were both 1.0 ?慊/mL. The application of the proposed method for determination of piracetam and levetiracetam in human plasma was demonstrated as well.

並列關鍵字

direct injection ； micellar electrokinetic chromatography ； pyrrolidone ； piracetam ； levetiracetam

參考文獻

[1] S. Shorvon, Pyrrolidone derivatives. Lancet 358 (2001) 1885–1892.

[2] C. Giurgea, M. Salama, Nootropic drugs. Prog Neuro- Psychopharmac 1 (1977) 235–247.

[3] B. Winblad, Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Rev 11 (2005) 169–182.

[4] W. E. Muller, S. Koch, K. Scheuer, A. Rostock, R. Bartsch, Effect of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol 53 (1997) 135–140.

[5] F. T. Crews, Effects of membrane fluidity on secretion and receptor stimulation. Psychopharmacol Bull 18 (1982) 135–143.